{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:39:09Z","timestamp":1792175949134,"version":"4.4.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to evaluate the safety and efficacy of a domestically developed implantable tibial neuromodulation system (iTNS) in the treatment of overactive bladder (OAB) in patients with urgency urinary incontinence (UUI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective single-center open-label trial was conducted. A total of 10 participants underwent iTNS device implantation, followed by device activation at 2\u20134 weeks post-implantation. Follow-up evaluations were performed at 1, 3, and 6 months post-implantation, including 3-day bladder diaries, validated questionnaires, and symptom satisfaction surveys. The primary endpoint was a \u226550% reduction in UUI episodes per day at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 6 months, the iTNS system achieved a 90% response rate (9\/10 patients), among whom 40% (4\/10) attained \u22653 consecutive dry days. A delayed therapeutic onset was observed: a significant reduction in UUI episodes emerged at 3 months (from 3.235 to 0.766 episodes per day) and 6 months (from 3.235 to 0.632 episodes per day). Quality of life was significantly improved at 6 months, as indicated by the changes in validated questionnaires (OAB-Q: 69.5\u00a0\u00b1\u00a011.76 to 44.4\u00a0\u00b1\u00a012.06; OABSS: 9\u00a0\u00b1\u00a01.155 to 6.2\u00a0\u00b1\u00a02.394). Additionally, 80% of patients reported satisfaction with their symptoms at the 6-month endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The domestically developed iTNS system is safe and effective for the treatment of UUI in patients with OAB. It exhibits a strong ability to significantly reduce or completely resolve UUI symptoms, with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1865760","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:47:05Z","timestamp":1784090825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of an implantable tibial neuromodulation system for overactive bladder with urgency urinary incontinence: an open-label, single arm trial"],"prefix":"10.3389","volume":"6","author":[{"given":"Fuyuan","family":"Zheng","sequence":"first","affiliation":[{"name":"School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology","place":["Shanghai, China"]},{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Guan","sequence":"additional","affiliation":[{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Fang","sequence":"additional","affiliation":[{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Song","sequence":"additional","affiliation":[{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Lv","sequence":"additional","affiliation":[{"name":"Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","article-title":"European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence","volume":"82","author":"Nambiar","year":"2022","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.04.020","article-title":"An overview of novel devices for tibial nerve stimulation in urinary incontinence","volume":"11","author":"Defour","year":"2025","journal-title":"Eur Urol Focus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.12.036","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: Results from the SUmiT trial","volume":"183","author":"Peters","year":"2010","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.05.045","article-title":"Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: Results from the overactive bladder innovative therapy trial","volume":"182","author":"Peters","year":"2009","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22251","article-title":"Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis","volume":"31","author":"Burton","year":"2012","journal-title":"NeurourolUrodyn"},{"key":"B6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ju.0000000000001733","article-title":"Pivotal study of leadless tibial nerve stimulation with eCoin\u00ae for urgency urinary incontinence: An open-label, single arm trial","volume":"206","author":"Rogers","year":"2021","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.01.078","article-title":"A new implanted posterior tibial nerve stimulator for the treatment of overactive bladder syndrome: 3-month results of a novel therapy at a single center","volume":"198","author":"Van Breda","year":"2017","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000004958","article-title":"Implantable tibial neuromodulation therapy improves symptoms of urge urinary incontinence from the TITAN 2 pivotal study","volume":"215","author":"Lee","year":"2026","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000005062","article-title":"Three-year efficacy and safety of Revi\u00ae implantable tibial neuromodulation from the pivotal OASIS study","author":"Amundsen","year":"2026","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.06.026","article-title":"Sacral neuromodulation with the InterStimTM system for intractable lower urinary tract dysfunctions (SOUNDS): Results of clinical effectiveness, quality of life, patient-reported outcomes and safety in a French multicenter observational study","volume":"7","author":"Chartier-Kastler","year":"2021","journal-title":"EurUrol Focus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12325-024-03019-0","article-title":"Sacral and implantable tibial neuromodulation for the management of overactive bladder: A systematic review and meta-analysis","volume":"42","author":"Amundsen","year":"2025","journal-title":"Adv Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-026-06538-2","article-title":"Impact of Revi\u00ae implantable tibial neuromodulation on quality of life in patients with urgency urinary incontinence","author":"Sutherland","year":"2026","journal-title":"Int Urogynecol J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/tau-2025-245","article-title":"Effect of a novel implantable tibial nerve stimulation system on overactive bladder in pigs","volume":"14","author":"Yu","year":"2025","journal-title":"Transl Androl Urol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00192-025-06217-8","article-title":"Impact of weekly application frequency on the efficacy of tibial nerve stimulation therapy in the treatment of overactive bladder","volume":"37","author":"Ergin","year":"2026","journal-title":"Int Urogynecol J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.31128\/ajgp-11-19-5142","article-title":"Overactive bladder syndrome: Management and treatment options","volume":"49","author":"Hutchinson","year":"2020","journal-title":"Aust J Gen Pract"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1865760\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:47:18Z","timestamp":1784090838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1865760\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":15,"alternative-id":["10.3389\/fruro.2026.1865760"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1865760","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1865760"}}